R. V. Chari, M. L. Miller, and W. C. Widdison, Antibody-drug conjugates: an emerging concept in cancer therapy, Angew Chem Int Ed Engl, vol.53, issue.15, pp.3796-827, 2014.

B. Pohlman, J. Sweetenham, and R. M. Maclis, Review of clinical radioimmunotherapy, Expert Rev Anticancer Ther, vol.6, issue.3, pp.445-61, 2006.

D. J. Fitzgerald, A. S. Wayne, R. J. Kreitman, and I. Pastan, Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates, Cancer Res, vol.71, issue.20, pp.6300-6309, 2011.

B. Nolting, Linker technologies for antibody-drug conjugates, Methods Mol Biol, vol.1045, pp.71-100, 2013.

T. M. Behr, D. M. Goldenberg, and W. S. Becker, Radioimmunotherapy of solid tumors: a review "of mice and men, Hybridoma, vol.16, issue.1, pp.101-107, 1997.

G. A. Wiseman, L. I. Gordon, and P. S. Multani, Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial, Blood, vol.99, issue.12, pp.4336-4378, 2002.

C. W. Scholz, A. Pinto, and W. Linkesch, 90 yttriumibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.31, issue.3, pp.308-321, 2013.

M. Wang, Y. Oki, and B. Pro, Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma, J Clin Oncol, vol.27, issue.31, pp.5213-318, 2009.

J. M. Vose, R. L. Wahl, and M. Saleh, Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas, J Clin Oncol, vol.18, issue.6, pp.1316-1339, 2000.

M. S. Kaminski, M. Tuck, and J. Estes, 131 Itositumomab therapy as initial treatment for follicular lymphoma, N Engl J Med, vol.352, issue.5, pp.441-450, 2005.

T. Liersch, J. Meller, and B. Kulle, Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver : five-year safety and efficacy results, J Clin Oncol, vol.23, issue.27, pp.6763-70, 2005.

J. F. Chatal, L. Campion, and F. Kraeber-bodere, Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group, J Clin Oncol, vol.24, issue.11, pp.1705-1716, 2006.

P. Y. Salaun, L. Campion, and C. Bournaud, Phase II trial of carcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J Nucl Med, vol.53, issue.8, pp.1185-92, 2012.

S. T. Tagawa, M. I. Milowsky, and M. Morris, Phase II study of lutetium-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer, Clin Cancer Res, vol.19, issue.18, pp.5182-91, 2013.

J. S. Batra, B. S. Karir, and S. Vallabhajosula, Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy ( 177 Lu-J591) with or without docetaxel for metastatic castrationresistant prostate cancer (mCRPC), J Clin Oncol, p.33, 2015.

S. A. Gulec, S. J. Cohen, A. L. Pennington, and Z. , Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a phase I single-dose escalation trial, Clin Cancer Res, vol.17, issue.12, pp.4091-100, 2011.

A. Younes, A. Gopal, and S. Smith, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed Hodgkin's lymphoma, J Clin Oncol, vol.30, issue.18, pp.2183-2192, 2012.

Q. M. Yang, J. Y. Hong, and Y. H. Ko, Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia, Onco Targets Ther, vol.7, pp.1717-1739, 2014.

B. Pro, R. Advani, and P. Brice, Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study, J Clin Oncol, vol.30, issue.18, pp.2190-2196, 2012.

H. Kantarjian, D. Thomas, and J. Jorgensen, Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukemia: a phase 2 study, Lancet Oncol, vol.13, issue.4, pp.403-414, 2012.

V. Ribraq, J. Dupuis, and H. Tilly, A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory Bcell non-Hodgkin lymphoma, Clin Cancer Res, vol.20, issue.1, pp.213-233, 2014.

I. Burris, . Ha, H. S. Rugo, and S. J. Vukelja, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -Positive breast cancer after HER2-directed therapy, J Clin Oncol, vol.29, issue.4, pp.398-405, 2010.

I. E. Krop, P. Lorusso, and K. D. Miller, A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capetitabine, J Clin Oncol, vol.30, issue.26, pp.3234-3275, 2012.

P. A. Ott, O. Hamid, and A. C. Pavlick, Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma, J Clin Oncol, vol.32, issue.32, pp.3659-66, 2014.

J. Bendell, M. Saleh, and A. A. Rose, Phase I/II study of the antibody-drug conjugate glembatuzumab vedotin in patients with locally advanced or metastatic breast cancer, J Clin Oncol, vol.32, issue.32, pp.3619-3644, 2014.

N. M. Tannir, A. Forero-torres, and R. Ramchandren, Phase I dose-escalation study ofn SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma, Invest New Drugs, vol.32, issue.6, pp.1246-57, 2014.

T. M. Illidge, M. Bayne, and N. S. Brown, Phase study of fractionated 131 I-rituximab in low-grade Bcell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy, Blood, vol.113, issue.7, pp.1412-1433, 2009.

A. Beck, Review of antibody-drug conjugates, Methods in molecular biology series: a book edited by Laurent Ducry, MAbs, vol.6, pp.30-33, 2014.

K. E. Mccabe and A. M. Wu, Positive progress in im-munoPET. Not just a coincidence, Cancer Biother Radiopharm, vol.25, issue.3, pp.253-61, 2010.

S. M. Knowles and A. M. Wu, Advances in Immuno-Positron Emission Tomography: antibodies for molecular imaging in oncology, J Clin Oncol, vol.30, issue.31, pp.3884-92, 2012.

P. S. Steeg, Heterogeneity of drug target rspression among metastatic lesions:lessons from a breast cancer autopsy program, Clin Cancer Res, vol.14, issue.12, pp.3643-3648, 2008.

B. M. Tijink, L. R. Perk, and M. Budde, 124)I-L19-SIP for immune-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy

, Eur J Nucl Med Mol Imaging, vol.36, issue.8, pp.1235-1279, 2009.

G. A. Van-dongen, M. C. Huisman, and R. Boellaard, 89-immuno-PET for imaging of long circulating drugs and disease targets: why, how, and when to be applied ?, Q J Nucl Med Mol Imaging, vol.59, issue.1, pp.18-38, 2015.

B. B. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley et al., Tumour-initiating cells:challenges and opportunities for anticancer drug discovery, Nat Rev Drug Discov, vol.8, issue.10, pp.806-829, 2009.

P. Sapra, M. Damelin, and J. Dijoseph, Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells, Mol Cancer Ther, vol.12, issue.1, pp.38-47, 2013.

F. Guerard, J. Barbet, -. Chatal, F. Kraeber-bodere, M. Cherel et al., Which radionuclide, carrier molecule and clinical indication for alphaimmunotherapy?, Q J Nucl Med, vol.59, issue.2, pp.161-168, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02415080

E. B. Golden and L. Apetoh, Radiotherapy and immunogenic cell death, Semin Radiat Oncol, vol.25, issue.1, pp.11-18, 2015.

T. Kim, R. N. Amaria, C. Spencer, A. Reuben, Z. A. Cooper et al., Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma, Cancer Biol Med, vol.114, pp.237-283, 2014.

M. Z. Dewan, A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb et al., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res, vol.15, issue.17, pp.5379-88, 2009.